#BreastCancer treatment DOESN'T cause a significant increase in second cancers, contrary to common belief. 2% increase in contralateral breast cancer and 3% increase in non-breast cancer. And only 7% of excess cancers attributable to adjuvant therapies. bmj.com/content/390/bm…

For all breast cancer patients. Check out this pod cast breastcancernow.org/about-us/podca…

We’re proud to support the Breast Health campaign - supporting proactive approaches to breast health through prevention and early detection. Visit buff.ly/xbdpG12 to explore the latest insights in breast cancer research and awareness or find a copy inside The Guardian

Lobular breast cancer statistics, 2025 📊 ILC = 1 in 10 BCs ⬆️ +2.8%/yr 🧬 HR+/HER2–: 90% 💊 Chemoresistant & worse survival in advanced stage 🕵️‍♂️ Often missed, underdetected, undertreated 👉 Not just "ductal-lite". ILC deserves its own spotlight.. acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn…

My Day 1 ESMO Breast Cancer Notes to take home #bcsm OncoAlert

Overall Survival with Abemaciclib in Early Breast Cancer annalsofoncology.org/article/S0923-… Presented at #ESMO25 The phase 3 monarchE 🦋trial shows that adding abemaciclib to adjuvant endocrine therapy significantly improves overall, invasive disease–free, and distant relapse–free

Have you read the ABS Mastectomy Avoidance Toolkit? A practical aid to reducing unnecessary mastectomies and supporting MDT decision making. Access the toolkit here: buff.ly/dmf6xpg

“Ever use of any hormonal contraceptive was associated with increased breast cancer risk (HR, 1.24) corresponding to 1 additional case per 7752 users.”

Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer 📌Chest-wall irradiation didn’t improve survival in intermediate-risk early breast cancer after mastectomy with modern systemic therapy. nejm.org/doi/full/10.10…

And they saw the NHS needs more managers… try radiology, pathology and oncologist… bbc.co.uk/news/articles/…

Just out! The 2025 St. Gallen International #BreastCancer Consensus — redefining individualized therapy for early breast cancer. From risk-adapted treatment to patient preference–driven decisions. #BreastCancer #StGallen2025 #Oncology #ESMO #CancerCare  LARVOL OncoAlert

Age and mutation-specific breast cancer risk👇 From Dr. Shani Paluch-Shimon’s presentation at #ESMO25

NCCN Breast Cancer Guidelines 2025 (v5) #update focuses on localized therapy: • Less extensive axillary surgery—SLN biopsy may replace ALND in select pts. • Hypofractionated post-mastectomy RT safe with reconstruction. • Partial breast irradiation recommended for low-risk pts

Interpreting liver blood test results can be challenging. How should clinicians interpret abnormal test results? New Education article offers guidance and a visual summary #BMJInfographic 🔗 bit.ly/4hYP9mF

NCCN Breast Cancer v5.2025 — Key Updates 🔍🎗️ The latest NCCN update continues the shift toward safe de-escalation in localized #BreastCancer : • Axilla SLNB can replace ALND in select patients → less morbidity with no compromise in outcomes. OncoAlert #bcsm

#NewProfilePic

Management of Cancer During Pregnancy: ASCO Guideline It is a remarkably comprehensive guide that addresses every question thoroughly👇 ascopubs.org/doi/10.1200/JC…

Less is more in the axilla at #SABCS25 💡🫁 #AXSANA shows that in cN1 → ypN0 after NACT, SLNB or TAD matches ALND for 3 year axillary control at ~99 percent 🎯 More surgery did not improve control. Smart de escalation preserves outcomes and quality of life 🌿 #medtwitter

🔥 PALLAS at #SABCS25 Final nail for adjuvant palbociclib ⚰️ 7 year follow up shows no iDFS, DRFS, or OS benefit with adjuvant palbociclib. Post recurrence OS appears shorter, driven by less CDK4/6 reuse and more visceral relapse. 🧪 Bottom line - palbociclib has no role in

We’re preparing for the largest #MiamiBreast yet. Make sure not to miss it. Free registration using TARANTINO as promo code here: registration.gotoper.com/mbcc-2026?_gl=…. See you there! 🏝️